Maintaining Our Takeda FVE Following Fiscal 1Q; Entyvio Strength, but Cautious on Oncology
Takeda’s first quarter of fiscal 2017 was strong, with underlying core growth in revenue (6.6%) and EPS (35.7%) ahead of our expectations as gross margins improved, efficiency measures continued, and a few one-time items (sales of Wako Pure Chemical, products to Teva Takeda, and real estate) added to earnings in the quarter. We’re maintaining our JPY 4,960 fair value estimate, as we expect weaker performance for the remainder of the year, including the possibility of generic versions of Velcade ...Takeda Pharmaceutical is a public company incorporated in Japan. Co. and its subsidiaries is a global pharmaceutical group and is engaged in the research, development, manufacturing and marketing of pharmaceutical products, over-the-counter (“OTC”) medicines and quasi-drug consumer products, and other healthcare products. Co.'s principal pharmaceutical products include medicines in the following therapeutic areas: gastroenterology, oncology and neuroscience.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.